Cargando…

Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study

Objectives: Osteoporosis and bone erosions are hallmarks of rheumatoid arthritis (RA) since disease onset is underpinned by the inflammatory burden. In this observational study, we aimed to dissect the putative RA-related parameters and bone-derived biomarkers associated with systemic and focal bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Dario, Fedele, Anna Laura, Tolusso, Barbara, Barini, Angelina, Petricca, Luca, Di Mario, Clara, Barini, Antonella, Mirone, Luisa, Ferraccioli, Gianfranco, Alivernini, Stefano, Gremese, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959810/
https://www.ncbi.nlm.nih.gov/pubmed/33732715
http://dx.doi.org/10.3389/fmed.2021.613889
_version_ 1783665031978680320
author Bruno, Dario
Fedele, Anna Laura
Tolusso, Barbara
Barini, Angelina
Petricca, Luca
Di Mario, Clara
Barini, Antonella
Mirone, Luisa
Ferraccioli, Gianfranco
Alivernini, Stefano
Gremese, Elisa
author_facet Bruno, Dario
Fedele, Anna Laura
Tolusso, Barbara
Barini, Angelina
Petricca, Luca
Di Mario, Clara
Barini, Antonella
Mirone, Luisa
Ferraccioli, Gianfranco
Alivernini, Stefano
Gremese, Elisa
author_sort Bruno, Dario
collection PubMed
description Objectives: Osteoporosis and bone erosions are hallmarks of rheumatoid arthritis (RA) since disease onset is underpinned by the inflammatory burden. In this observational study, we aimed to dissect the putative RA-related parameters and bone-derived biomarkers associated with systemic and focal bone loss at disease onset and with their progression. Methods: One-hundred twenty-eight patients with early rheumatoid arthritis (ERA) were recruited at disease onset. At study entry, demographic, clinical, and immunological parameters were recorded. Each ERA patient underwent plain X-rays of the hands and feet at study entry and after 12 months to assess the presence of erosions. After enrollment, each patient was treated according to the recommendations for RA management and followed up based on a treat-to-target (T2T) strategy. At baseline, blood samples for soluble biomarkers were collected from each patient, and plasma levels of osteoprotegerin (OPG), receptor activator of nuclear factor κB ligand (RANKL), Dickkopf-1 (DKK1), and interleukin 6 (IL-6) were assessed by enzyme-linked immunosorbent assay (ELISA). Seventy-one ERA patients underwent bone mineral density (BMD) measurement at the left femoral neck and second to fourth lumbar spine vertebrae (L2–L4) by dual-energy X-ray absorptiometry (DXA). Results: Among the whole cohort, 34 (26.6%) ERA patients with bone erosions at study entry had a higher disease activity (p = 0.02) and IL-6 plasma levels (p = 0.03) than non-erosive ones. Moreover, at DXA, 33 (46.5%) ERA patients had osteopenia, and 16 (22.5%) had osteoporosis; patients with baseline bone erosions were more likely osteopenic/osteoporotic than non-erosive ones (p = 0.03), regardless of OPG, RANKL, and DKK1 plasma levels. Obese ERA patients were less likely osteopenic/osteoporotic than normal weight ones (p = 0.002), whereas anti-citrullinated protein antibodies (ACPA) positive ERA patients were more likely osteopenic/osteoporotic than ACPA negative ones (p = 0.034). At logistic regression analysis, baseline Disease Activity Score measured on 44 joints (DAS44) [OR: 2.46 (1.11–5.44)] and osteopenic/osteoporosis status [OR: 7.13 (1.27–39.94)] arose as independent factors of erosiveness. Baseline osteopenic/osteoporotic status and ACPA positivity were associated with bone damage progression during the follow-up. Conclusions: Bone erosions presence is associated with systemic bone loss since the earliest phases of RA, suggesting that the inflammatory burden and autoimmune biology, underpinning RA, represent crucial enhancers of bone remodeling either locally as at systemic level.
format Online
Article
Text
id pubmed-7959810
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79598102021-03-16 Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study Bruno, Dario Fedele, Anna Laura Tolusso, Barbara Barini, Angelina Petricca, Luca Di Mario, Clara Barini, Antonella Mirone, Luisa Ferraccioli, Gianfranco Alivernini, Stefano Gremese, Elisa Front Med (Lausanne) Medicine Objectives: Osteoporosis and bone erosions are hallmarks of rheumatoid arthritis (RA) since disease onset is underpinned by the inflammatory burden. In this observational study, we aimed to dissect the putative RA-related parameters and bone-derived biomarkers associated with systemic and focal bone loss at disease onset and with their progression. Methods: One-hundred twenty-eight patients with early rheumatoid arthritis (ERA) were recruited at disease onset. At study entry, demographic, clinical, and immunological parameters were recorded. Each ERA patient underwent plain X-rays of the hands and feet at study entry and after 12 months to assess the presence of erosions. After enrollment, each patient was treated according to the recommendations for RA management and followed up based on a treat-to-target (T2T) strategy. At baseline, blood samples for soluble biomarkers were collected from each patient, and plasma levels of osteoprotegerin (OPG), receptor activator of nuclear factor κB ligand (RANKL), Dickkopf-1 (DKK1), and interleukin 6 (IL-6) were assessed by enzyme-linked immunosorbent assay (ELISA). Seventy-one ERA patients underwent bone mineral density (BMD) measurement at the left femoral neck and second to fourth lumbar spine vertebrae (L2–L4) by dual-energy X-ray absorptiometry (DXA). Results: Among the whole cohort, 34 (26.6%) ERA patients with bone erosions at study entry had a higher disease activity (p = 0.02) and IL-6 plasma levels (p = 0.03) than non-erosive ones. Moreover, at DXA, 33 (46.5%) ERA patients had osteopenia, and 16 (22.5%) had osteoporosis; patients with baseline bone erosions were more likely osteopenic/osteoporotic than non-erosive ones (p = 0.03), regardless of OPG, RANKL, and DKK1 plasma levels. Obese ERA patients were less likely osteopenic/osteoporotic than normal weight ones (p = 0.002), whereas anti-citrullinated protein antibodies (ACPA) positive ERA patients were more likely osteopenic/osteoporotic than ACPA negative ones (p = 0.034). At logistic regression analysis, baseline Disease Activity Score measured on 44 joints (DAS44) [OR: 2.46 (1.11–5.44)] and osteopenic/osteoporosis status [OR: 7.13 (1.27–39.94)] arose as independent factors of erosiveness. Baseline osteopenic/osteoporotic status and ACPA positivity were associated with bone damage progression during the follow-up. Conclusions: Bone erosions presence is associated with systemic bone loss since the earliest phases of RA, suggesting that the inflammatory burden and autoimmune biology, underpinning RA, represent crucial enhancers of bone remodeling either locally as at systemic level. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7959810/ /pubmed/33732715 http://dx.doi.org/10.3389/fmed.2021.613889 Text en Copyright © 2021 Bruno, Fedele, Tolusso, Barini, Petricca, Di Mario, Barini, Mirone, Ferraccioli, Alivernini and Gremese. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Bruno, Dario
Fedele, Anna Laura
Tolusso, Barbara
Barini, Angelina
Petricca, Luca
Di Mario, Clara
Barini, Antonella
Mirone, Luisa
Ferraccioli, Gianfranco
Alivernini, Stefano
Gremese, Elisa
Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study
title Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study
title_full Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study
title_fullStr Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study
title_full_unstemmed Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study
title_short Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study
title_sort systemic bone density at disease onset is associated with joint erosion progression in early naive to treatment rheumatoid arthritis: a prospective 12-month follow-up open-label study
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959810/
https://www.ncbi.nlm.nih.gov/pubmed/33732715
http://dx.doi.org/10.3389/fmed.2021.613889
work_keys_str_mv AT brunodario systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT fedeleannalaura systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT tolussobarbara systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT bariniangelina systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT petriccaluca systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT dimarioclara systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT bariniantonella systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT mironeluisa systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT ferraccioligianfranco systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT aliverninistefano systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy
AT gremeseelisa systemicbonedensityatdiseaseonsetisassociatedwithjointerosionprogressioninearlynaivetotreatmentrheumatoidarthritisaprospective12monthfollowupopenlabelstudy